Premature Aging and Type 2 Diabetes Mellitus: an Increased Risk of Cardiomyopathy? (R2D2)
The potential clinical implications of this study are to optimise the selection of a population at risk for developing a diabetic cardiomyopathy among diabetic patients in order to develop early therapeutic strategies to prevent the left ventricular remodelling.
Therefore, the originality of this project is to hypothesize that :
- Diabetes mellitus is often associated with a premature aging syndrome
- Cellular senescence may potentiate the mechanisms that are involved in decreasing myocardial contractility in DM and,
- DM associated to premature aging may increase the risk of developing a cardiomyopathy Thus, the modulation of telomerase activity and the control of telomere length, together with the attenuation of the formation of reactive oxygen species, might represent important new targets in order to develop therapeutic tools in prevention of diabetic cardiomyopathy.
|Type 2 Diabetes Mellitus||Other: Cardiac RMI Other: Analysis telomere Other: Stress test Other: echocardiography|
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||Premature Aging and Type 2 Diabetes Mellitus: an Increased Risk of Cardiomyopathy?|
- Telomere shortening [ Time Frame: 36 months ]Investigate whether biomarkers for senescence determined from blood samples, including telomere shortening and telomerase activity in diabetic patients have an impact of left ventricular remodelling as compared with age-matched controls and biological aged control subjects.
- Dysfunction by speckle tracking imaging [ Time Frame: 36 months ]Study the incidence of subtle regional myocardial dysfunction by speckle tracking imaging (longitudinal and radial systolic strain)
- Determine the predictive value of alteration [ Time Frame: 36 months ]Determine the predictive value of alteration : Proteinuria, glycosylated haemoglobin, diabetes mellitus duration, blood pressure, BNP dosage, MRI diagnoses
- Cardiovascular events [ Time Frame: 36 months ]Investigate the predictive value of all those factors( telomere shortening, telomerase activity, echo abnormalities) on cardiovascular events including MI, HF, arrhythmia; ACV
|Study Start Date:||April 2009|
|Study Completion Date:||December 2014|
|Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Other: Cardiac RMI
Please refer to this study by its ClinicalTrials.gov identifier: NCT01536808
|Bron, France, 69500|
|Principal Investigator:||Geneviève Dérumeaux, Pr||Hospices Civils de Lyon - Hôpital Louis Pradel|